DOI QR코드

DOI QR Code

Clinical Application of Recombinant Human Endostatin in Postoperative Early Complementary Therapy on Patients with Non-small Cell Lung Cancer in Chinese Mainland

  • Zhu, Qiang (Department of Thoracic Surgery, The Affiliated Qianfoshan Hospital of Shandong University) ;
  • Zang, Qi (Department of Thoracic Surgery, The Affiliated Qianfoshan Hospital of Shandong University) ;
  • Jiang, Zhong-Min (Department of Thoracic Surgery, The Affiliated Qianfoshan Hospital of Shandong University) ;
  • Wang, Wei (Department of Thoracic Surgery, The Affiliated Qianfoshan Hospital of Shandong University) ;
  • Cao, Ming (Department of Thoracic Surgery, The Affiliated Qianfoshan Hospital of Shandong University) ;
  • Su, Gong-Zhang (Department of Thoracic Surgery, The Affiliated Qianfoshan Hospital of Shandong University) ;
  • Zhen, Tian-Chang (Department of Thoracic Surgery, The Affiliated Qianfoshan Hospital of Shandong University) ;
  • Zhang, Xiao-Tian (Weifang Medical University) ;
  • Sun, Ning-Bo (Weifang Medical University) ;
  • Zhao, Cheng (Shandong University School of Medicine)
  • Published : 2015.05.18

Abstract

Objective: To explore the clinical application of recombinant human endostatin (Endostar) in the treatment of patients with non-small cell lung cancer (NSCLC) in Chinese mainland. Materials and Methods: A total of 75 patients diagnosed as NSCLC were randomly divided into control group (37 cases) and treatment group (38 cases). Control group was treated with postoperative complementary chemotherapy containing two-agent platinum protocol on postoperative d21, 3 weeks as a cycle, for totally 4~6 cycles. On this basis, treatment group was added with Endostar $7.5mg/m^2$ on postoperative d8~9, 3~4 h/time, qd, 14 weeks as a cycle, for totally 4 cycles. The interval between every two cycles was 7 d. The 5-year progression-free survival (PFS), 5-year survival time and complications in both groups were observed. Results: Compared with control group, the average PFS increased evidently in treatment group by 9.8 months (41.6 months vs. 31.8 months), and there was significant difference (P<0.05). And the median PFS was 42.5 months in treatment group, obviously longer than that in control group (33.7 months) by 8.8 months (P<0.05). Additionally, the 5-year overall survival rate (OS), average survival time and median survival time (MST) were 47.4%, 50.1 months and 59.3 months in treatment group, significantly higher than the 29.7%, 42.1 months and 43.5 months in control group (P<0.05). Only 1 patient showed poor healing of surgical wound in treatment group, but no surgery-associated complication was found in control group. Moreover, the postoperative complementary therapy-connected complication rates were 63.2% (24/38) and 59.5% (22/37) in treatment group and control group respectively, but there was no significant difference (P>0.05). Conclusions: The application of Endostar combined with sensitive platinum-contained chemotherapeutic agents in the postoperative complementary chemotherapy can be widely used in clinic because it can significantly prolong the long-term survival time of patients with NSCLC.

Keywords

Non-small cell lung cancer;recombinant human endostatin;postoperative complementary chemotherapy;progression-free survival;overall survival rate

References

  1. Calvo A, Yokoyama Y, Smith LE, et a1 (2002). Inhibition of the mammary carcinoma angiogenic switch in C3 (1)/SV40 transgenic mice by a mutated form of human endostatin. Int J Cancer, 101, 224-34. https://doi.org/10.1002/ijc.10589
  2. Cui L, Liu XX, Jiang Y, et al (2014). Phase II study on dose escalating schedule of paclitaxel concurrent with radiotherapy in treating patients with locally advanced non-small cell lung cancer. Asian Pac J Cancer Prev, 15, 1699-702. https://doi.org/10.7314/APJCP.2014.15.4.1699
  3. Dass CR, Choong PF (2008). Cancer angiogenesis: targeting the heel of Achilles. Drug Target, 16, 449-54. https://doi.org/10.1080/10611860802088523
  4. Dong X P, Xiao T H, Dong H, et al (2013). Endostar combined with cisplatin inhibits tumor growth and lymphatic metastasis of lewis lung carcinoma xenografts in mice. Asian Pac J Cancer Prev, 14, 3079-83. https://doi.org/10.7314/APJCP.2013.14.5.3079
  5. Fei ZH, Yao CY, Yang XL, et al (2013). Serum BMP-2 up-regulation as an indicator of poor survival in advanced non-small cell lung cancer patients. Asian Pac J Cancer Prev, 14, 5293-9. https://doi.org/10.7314/APJCP.2013.14.9.5293
  6. Felip E, Rosell R (2002). Neoadjuvant chemotherapy in non-small cell lung cancer. Curr Med Chem, 9, 893-8. https://doi.org/10.2174/0929867024606768
  7. Folkman J (1971). Tumor angiogenesis: therapeutic implications. N Engl J Med, 285, 1182-6. https://doi.org/10.1056/NEJM197111182852108
  8. Folkman J (2006). Anti-angiogenes in cancer theraphy-endostatin and its mechanisms of action. Expt Cell Res, 312, 594-607. https://doi.org/10.1016/j.yexcr.2005.11.015
  9. Globocan 2012: estimated cancer incidence, mortality and prevalence worldwide in 2012. http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx.
  10. Hou ZB, Lu KJ, Wu XL, et al (2014). In vitro and in vivo antitumor evaluation of berbamine for lung cancer treatment.Asian Pac J Cancer Prev, 15, 1767-9. https://doi.org/10.7314/APJCP.2014.15.4.1767
  11. Huang G, Chen L (2010). Recombinant human endostatin improves anti-tumor efficacy of paclitaxel by normalizing tumor vasculature in Lewis lung carcinoma. J Cancer Res Clin Oncol, 136, 1201-11. https://doi.org/10.1007/s00432-010-0770-6
  12. Huang XE, Tian GY, Cao J, et al (2014). Pemetrexed as a component of first-, second- and third- line chemotherapy in treating patients with metastatic lung adenocarcinoma. Asian Pac J Cancer Prev, 14, 6663-7.
  13. Ji ZQ, Huang XE, Wu XY, et al (2014). Safety of Brucea javanica and cantharidin combined with chemotherapy for treatment of NSCLC patients. Asian Pac J Cancer Prev, 15, 8603-5. https://doi.org/10.7314/APJCP.2014.15.20.8603
  14. Jiang XD, Dai P, Qiao Y, et al (2012). Clinical study on the recombinant human endostatin regarding improving the blood perfusion and hypoxia of non-small-cell lung cancer. Clin Transl Oncol, 14, 437-43. https://doi.org/10.1007/s12094-012-0821-3
  15. Lu YY, Huang XE, Cao J, et al (2013). Phase II study on Javanica oil emulsion injection (Yadanzi$^{(R)}$) combined with chemotherapy in treating patients with advanced lung adenocarcinoma. Asian Pac J Cancer Prev, 14, 4791-4. https://doi.org/10.7314/APJCP.2013.14.8.4791
  16. Kaya M, Wada T, Nagoya S, et al (2007). Prevention of postoperative progression of pulmonary metastases in osteosarcoma by antiangiogenic therapy using endostatin. J Orthop Sci, 12, 562-7. https://doi.org/10.1007/s00776-007-1179-1
  17. Kirsch M, Strasser J, Allende R, et al (1998). Angiostatin suppress malignant glioma growth in vivo. Cancer Res, 58, 4654-9.
  18. Li N, Zheng DW, Wei XY, et al (2012). Effects of recombinant human endostatin and its synergy with cisplatin on circulating endothelial cells and tumor vascular normalization in A549 xenograft murine model. J Cancer Res Clin Oncol, 138, 1131-44. https://doi.org/10.1007/s00432-012-1189-z
  19. Liu ZJ, Wang J, Wei XY, et al (2012). Predictive value of circulating endothelial cells for efficacy of chemotherapy with Rh-endostatin in non-small cell lung cancer. J Cancer Res Clin Oncol, 138, 927-37. https://doi.org/10.1007/s00432-012-1167-5
  20. Macpherson GR, Ng SS, Forbes SL, et al (2003). Anti-angiogenic activity of human endostatin is HIF-1-independent in vitro and sensitive to timing of treatment in a human saphenous vein assay. Mol Cancer Ther, 2, 845-54.
  21. Peng XC, Qiu M, Wei M, et al (2012). Different combination schedules of gemcitabine with endostar affect antitumor efficacy. Cancer Chemother Pharmacol, 69, 239-46. https://doi.org/10.1007/s00280-011-1695-8
  22. Rong B, Yang S, Li W, et al (2012). Systematic review and meta-analysis of Endostar (rh-endostatin) combined with chemotherapy versus chemotherapy alone for treating advanced non-small cell lung cancer. World J Surg Oncol, 10, 170. https://doi.org/10.1186/1477-7819-10-170
  23. Rosell R, Felip E, Maestre J, et al (2001). The role of chemotherapy inearly non-small-cell lung cancer management. Lung Cancer, 34, S63-S74. https://doi.org/10.1016/S0169-5002(01)00376-2
  24. Scappaticci FA, Fehrenbacher L, Cartwright T (2005). Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab. J Surg Oncol, 91, 173-80. https://doi.org/10.1002/jso.20301
  25. Shojaei F, Ferrara N (2008). Role of the microenvironment in tumor growth and in refractoriness/resistance to anti-angiogenenic therapies. Drug Resist Updat, 11, 219-30. https://doi.org/10.1016/j.drup.2008.09.001
  26. Sim BKL, O, Reilly MS, Liang H, et al (1997). A recombinant human angiostatin protein inhibits experimental primary and metastatic cancer. Cancer Res, 57, 1329-34.
  27. Tatyana L, Diptiman C, Lisa K, et al (2007). Effects 0f sustained antiangiogenic therapy in multistage prostate cancer in TRAMP model. Cancer Res, 67, 5789-97. https://doi.org/10.1158/0008-5472.CAN-06-3637
  28. Te Velde EA, Reijerkerk A, Brandsma D, et al (2005). Early endostatin treatment inhibits metastatic seeding of murine colorectal cancer cells in the liver and their adhesion to endothelial cells. Br J Cancer, 92, 729-35. https://doi.org/10.1038/sj.bjc.6602385
  29. Tsunemi T, Nagoya S, Kaya M, et al (2003). Postoperative progression of pulmonary metastasis in osteosarcoma. Clin Orthop Relat Res, 407, 159-66. https://doi.org/10.1097/00003086-200302000-00024
  30. Wang HL, Ning T, Li M, et al (2011). Effect of endostatin on preventing postoperative progression of distant metastasis in a murine lung cancer model. Tumori, 97, 787-93.
  31. Wang JW, Sun Y, Liu YY, et al (2005). Results of randomized, multicenter, double-blind phase III trial of rh-endostatin (YH-16) in treatment of advanced non-small cell lung cancer patients. Chin J Lung Cancer, 8, 283-90.
  32. Wu HT, Deng J, Yu SY, et al (2010). The Inhibitory Effects of Rh-endostatin (YH-16) in Combination with Radiotherapy on lung adenocarcinoma A549 in Mice and the Underlying Mechanisms. J Huazhong Univ Sci Technol, 30, 108-12. https://doi.org/10.1007/s11596-010-0120-6
  33. Xia H, Luo L M, Fan Y F, et al (2003). Inhibitory effect of recombinant human endostatin on angiogenesis and lung metastasis of mouse lung adenocarcinoma, LA795. J First Mil Med Univ, 23, 30-3.
  34. Yan HA, Shen K, Huang XE (2013). Clinical study on mannan peptide combined with TP regimen in treating patients with non-small cell lung cancer. Asian Pac J Cancer Prev, 14, 4801-4. https://doi.org/10.7314/APJCP.2013.14.8.4801
  35. Yao HC, Jin DJ, Sun YN, et al (2004). Endostatin in the treatment of the transplantable model of human laryngeal squamous carcinoma in nude mice. Chinese J Otorhinolaryngol, 39, 394-8.

Cited by

  1. antitumor effect of endostatin-loaded chitosan nanoparticles combined with paclitaxel on Lewis lung carcinoma vol.24, pp.1, 2017, https://doi.org/10.1080/10717544.2017.1378938
  2. The antitumour effects of eudesmin on lung cancer by inducing apoptosis via mitochondria-mediated pathway in the tumour cells vol.55, pp.1, 2017, https://doi.org/10.1080/13880209.2017.1401647